Ramsay Health Care has clarified that its underlying earnings for FY25 aligned closely with market consensus, despite a significant non-cash impairment impacting statutory profits. The company confirms compliance with ASX disclosure rules amid share price volatility.
- Underlying NPAT and EBIT in line with sell-side analyst consensus
- Significant $291m non-cash impairment on UK mental health business impacted statutory NPAT
- Statutory NPAT deemed less relevant by market due to impairment size
- No material variance requiring earlier market disclosure identified
- Share price decline linked to FY26 outlook and UK business challenges
Context of the ASX Aware Letter
Ramsay Health Care Limited (RHC) recently responded to an ASX Aware Letter following its FY25 full-year results announcement. The letter from ASX Compliance sought clarity on whether Ramsay’s reported earnings deviated materially from market expectations and whether the company complied with continuous disclosure obligations under the ASX Listing Rules.
Underlying vs Statutory Earnings
Ramsay Health Care emphasised that its key earnings metrics for investors and analysts are Underlying Net Profit After Tax (NPAT) and Underlying Earnings Before Interest and Tax (EBIT). These metrics exclude significant one-off items and provide a clearer picture of operational performance. The company reported an Underlying NPAT of $305.3 million and Underlying EBIT of $1,042.6 million for FY25, figures that were closely aligned with the consensus estimates from 16 sell-side analysts.
In contrast, Statutory NPAT was reported at a much lower $24.0 million, heavily impacted by a $291 million non-cash impairment related to the UK mental health business, Elysium Healthcare. This impairment reflected underperformance against acquisition plans and was announced prior to the half-year results. Due to the size and nature of this impairment, both Ramsay and analysts considered Statutory NPAT an unreliable indicator of the company’s ongoing earnings performance for FY25.
Market Expectations and Disclosure Compliance
Ramsay confirmed it does not publish earnings guidance, so market expectations were gauged through analyst consensus. The company’s internal forecasting processes showed it was operating materially in line with these consensus estimates throughout the reporting period. Ramsay stated that no material variance arose that would have necessitated earlier disclosure under Listing Rules 3.1 and 3.1A.
The company also addressed the share price decline following the results announcement, attributing it primarily to the FY26 outlook, ongoing challenges in the UK mental health segment, and the absence of new information regarding the strategic review of its majority stake in Ramsay Santé. Ramsay affirmed it remains compliant with ASX continuous disclosure obligations and that its responses were authorised by its Disclosure Committee.
Looking Ahead
While Ramsay’s underlying earnings met expectations, the significant impairment and operational challenges in the UK highlight areas of risk and uncertainty. Investors will be watching closely for updates on the UK business turnaround and any developments in the strategic review of Ramsay Santé. The company’s ability to maintain transparent communication will be critical in managing market confidence going forward.
Bottom Line?
Ramsay’s FY25 underlying earnings steadiness masks ongoing UK challenges that could shape its next chapter.
Questions in the middle?
- How will Ramsay address the operational issues in its UK mental health business moving forward?
- What timeline and outcomes can investors expect from the strategic review of Ramsay Santé?
- Could further impairments or adjustments impact Ramsay’s statutory earnings in FY26?